Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) SHH

Currency In CNY

AD

Valuation

Market Cap10.29B
Enterprise Value10.4B
P/E Ratio154.44
PEG Ratio3.57
Price/Sales Ratio11.29
Price/Book Ratio9.39
Enterprise/Revenue11.6
Enterprise/EBITDA101.33

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin0.07
Operating Margin0.09
AD

Management Effectiveness

Return On Assets0.03
Return On Equity0.06

Income Statement

Revenue704.16M
Revenue/Share1.91
Gross Profit704.16M
EBITDA59.85M
Net Income22.23M
Diluted EPS0.05

Balance Sheet

Total Cash194.9M
Total Cash/Share0.48
Total Debt434.93M
Total Debt/Equity0.47
Current Ratio1.36
Book Value Per Share2.3

Price History

52-Week Change2.33
52-Week High44.9
52-Week Low19.99
Moving Average 50 Days34.47
Moving Average 200 Days29.33

Statistics

Average Volume13.27M
Shares Outstanding405.41M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0.21
Last Split FactorN/A
Last Split DateN/A
AD